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a b s t r a c t
We report on an 8 year old boy with primary cardiac anaplastic large cell lymphoma (ALCL), in whom the
diagnosis was challenging and who was treated with modiﬁed chemotherapy without radiation therapy
according to the ALCL 99 study protocol [1]. Two years and 4 months after completion of therapy the boy
is in complete remission with normal cardiac function.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Report
We report on an 8 year old boy with primary cardiac anaplastic
large cell lymphoma (ALCL), in whom the diagnosis was challen-
ging and who was treated with modiﬁed chemotherapy without
radiation therapy according to the ALCL 99 study protocol [1].
Two years and 5 months after completion of therapy the boy is in
complete remission with normal cardiac function.
The boy was admitted with history of recurrent colds, weight
loss, joint pain and fever up to 40 1C. Laboratory tests showed
normal complete blood count and differentiation, normal electro-
lytes and renal function tests. ALAT (199 U/L), ASAT (152 U/L),
LDH (528 U/L), NT-proBNP (735 ng/L) and Troponine-T (5.35 ng/L)
were elevated. Chest X-ray revealed moderate cardiomegaly. ECG
showed negative T-waves in V1-V6 and echocardiography (M-
Mode) revealed normal right and left ventricular function, mild
pericardial effusion and prominent masses in the left ventricular
apex (largest: 1.3 cm). Clinically, the boy felt weak, he had palpable
precordial heaving, peripheral oedema and hepatosplenomegaly
were not noticed. Tissue Doppler echocardiography measuring
myocardial velocity conﬁrmed reduced left ventricular function.
Due to positive mycoplasma serum-IgG and -IgM antibodies
antibiotic therapy was initiated. Cardiac magnetic resonance
imaging (MRI) was performed. It conﬁrmed a tumour in the apex
of the left ventricle and showed inﬁltration of the interventricular
septum and the right ventricle. On both sides tumours protruded
into the cavities (Fig. 1a). Left heart catheter showed good left
ventricular ejection fraction (EF, 56%) with muscular thickening
and irregular contrast enhancement of soft tissue within the left
cavity. Multiple catheter assisted biventricular myocardial biopsies
showed mild ﬁbrosis. They raised no suspicion of malignancy.
Within the following 2 weeks, moderate leucopenia (minimum
2.9/nL, neutrophils 39%, lymphocytes 49%) prompted bone mar-
row aspiration, which did not reveal a haematologic malignancy.
Serologic tests for Echo-, Coxsackie-, Polio- and Cytomegaly-virus
and HIV remained negative.
MRI of the abdomen and CNS as well as skeletal scintigraphy
showed no abnormalities apart from moderate hepatosplenome-
galy. Since the patient's clinical status deteriorated within another
2 weeks, pericardial puncture and second bone marrow aspiration
were performed with no pathologic ﬁndings. Ultimately, open
heart biopsy led to the diagnosis of an anaplastic lymphoma
kinase-1 (ALK-1) positive ALCL of lymphohistiocytic subtype
(positivity for CD30, CD2, CD3, granzyme-B, perforin, EMA and
ALK1) with monoclonal T-cell receptor rearrangement.
Prednisone prephase was initiated and led to immediate improve-
ment of clinical status. However, tumour size did not decrease within
the prolonged prephase of 11 days (Fig. 1b). Despite additional
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cyclophosphamide (2200 mg/m2), the patient showed deteriorating
clinical condition and fever reappeared 1 week later. Pleural effusion
and paravertebral cutaneous inﬁltration of the lymphoma indicated
progressive disease. Consequently, the ﬁrst AM block according to
ALCL99 was started (no methotrexate due to pericardial effusion).
During AM block, cardiac arrhythmia appeared and on day 6,
ventricular tachycardia with hemodynamic instability resistant to
chemical cardioversion occurred. Electric cardioversion and initiation
of amiodarone terminated ventricular arrhythmias and normalised
clinical status. The following cardiac MRI documented satisfying
reduction of tumour size (Fig. 1c). Further ALCL99 treatment was
given without modiﬁcation. After 6 AM/BM blocks, 2-deoxy-2-(18F)
ﬂuoro-D-glucose positron emission tomography/computed tomogra-
phy (FDG-PET/CT) suggested residual active tumour in the apex of the
heart. Additionally, cardiac MRI revealed a large thrombus within a
hypokinetic area in the apex of the left ventricle mandating warfarin
therapy. We were aware that residual tumour may not necessarily
predict active disease. Nevertheless, we decided to add 2 AM/BM
blocks since our patient had tolerated therapy well and cumulative
doses of chemotherapeutics with potential late effects (etoposide,
anthracyclines) permitted intensiﬁcation. Chemotherapy was com-
pleted 6 months after initiation of treatment (cumulative doses:
prednisone 1000 mg/m2, dexamethasone 400 mg/m2, ifosfamide
3200 mg/m2, cytosine arabinoside 2400 mg/m2, etoposide 800 mg/
m2, cyclophosphamide 4400 mg/m2, doxorubicin 200 mg/m2, meth-
otrexate 21 g/m2).
Since end of treatment no tumour growth has been seen in
cardiac MRI (Fig. 1d), FDG-PET/CT or echocardiography and the
patient is back to his former active life. The only evident sequela
two years after completion of therapy is a left ventricular scar,
which does not inﬂuence myocardial function.
Non-Hodgkin-Lymphomas (NHL) account for o10% of malig-
nant tumours in childhood and 10–15% of childhood NHL are ALK-
positive ALCL. More than 90% of childhood ALK-positive ALCL are
characterised by NPM-ALK-fusion proteins from a reciprocal
translocation t(2;5) [2]. In childhood ALCL, different chemotherapy
protocols reach an EFS of 65–75% [1,3,4], the 5 year overall survival
is 490% [1,4]. Treatment failure most often occurs within
6 months after the end of treatment. Relapse later than 3 years
after initiation of therapy or 2 years after completion of che-
motherapy is rare [1,4].
Primary cardiac tumours are most often observed in adulthood.
Within the group of cardiac tumours, lymphomas represent o2%
[5,6] and childhood cardiac lymphomas have only been reported
in case reports [7–9]. However, primary cardiac childhood ALCL
has not been described before and in the German paediatric NHL-
BFM and the European ALCL99 studies, in which nearly 100% of all
children with this disease are registered, no patient with cardiac
ALCL was registered within the last 3 decades [1,4].
Clinically, cardiac tumours are responsible for a variety of
symptoms, depending on the cardiac site of involvement. Com-
monly seen are chest pain, pericardial effusion, arrhythmias,
coronary sinus obstruction and congestive heart failure [6,10].
In our patient recurrent colds, weight loss, joint pains and fever
prompted the diagnostic work-up. Remarkably, even though
diagnostic work-up had shown a FDG-PET/CT positive cardiac
mass, neither pericardial effusion cytology nor myocardial biopsies
via cardiac catheterisation could conﬁrm the diagnosis.
Our clinical concern was whether myocardial function would
be retained after treatment of myocardial lymphoma. Since the
myocardium showed pathological contrast enhancement through-
out the ventricular wall, ventricular rupture would have been the
worst complication. Therefore, prednisone prephase was pro-
longed and intensiﬁed by cyclophosphamide. For better manage-
ment, treatment was monitored on the paediatric cardiology
intensive care unit with standby cardiac surgery and extracorpor-
eal membrane oxygenation facility. However, other than severe
cardiac arrhythmias including one episode of ventricular tachy-
cardia, therapy was well tolerated. From the second block (BM)
onwards, chemotherapy could be given without dose reductions.
To our best knowledge, this is the ﬁrst report on a child with
primary cardiac ALCL surviving after chemotherapy without addi-
tional treatment.
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Fig. 1. Cardiac MRI before and during ALCL treatment, Cardiac tumour shown by MR imaging before treatment (a), after prednisone prephase (b), after the ﬁrst AM block (c),
and two years after completion of therapy (d).
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